Immune-Related Adverse Events in Cancer Patients—From Pathophysiology to Treatment and Associations with Outcomes

Dear Colleagues,

Immunotherapy represents one of the most effective systemic anticancer therapies; it has been substantially developed in recent years, leading to great progress in the treatment of a wide spectrum of malignancies. Immunotherapy is usually accompanied by specific immune-related side events (irAEs) caused by impairment of immunotolerance to nontumoral tissues. The aims of understanding the pathophysiologic mechanisms underlying irAEs, finding predictive biomarkers, and developing optimal treatment strategies are of great importance in current experimental and clinical research. Moreover, there is an increasing body of evidence that the development of irAEs is associated with effects of immunotherapy; however, this association remains poorly understood. Additionally, there is an increasing number of agents influencing the immune system, used across various medical disciplines in different indications, with largely unknown impacts on cancer immunotherapies and their irAEs.

This Special Issue of Cells will present research articles and reviews that cover the scope of irAEs from the point of view of both experimental and clinical researchers. The articles should focus on various aspects of irAEs, including their pathophysiology, predictive biomarkers, treatment strategies, and associations with outcomes for patients. All scientists working in these fields are cordially invited to submit their manuscripts. We are looking forward to your contributions to this Special Issue.

Dr. Ondřej Fiala
Dr. Václav Vaněček
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunotherapy
• adverse effects
• irAE
• pathophysiology
• prediction
• outcome
• efficacy
• outcome